PMID- 30311424
OWN - NLM
STAT- MEDLINE
DCOM- 20191114
LR  - 20210109
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 7
IP  - 11
DP  - 2018 Nov
TI  - Safety of combined PD-1 pathway inhibition and radiation therapy for 
      non-small-cell lung cancer: A multicentric retrospective study from the GFPC.
PG  - 5505-5513
LID - 10.1002/cam4.1825 [doi]
AB  - INTRODUCTION: Randomized prospective studies on patients with metastatic 
      non-small-cell lung cancers (NSCLCs) showed that anti-programmed death-1 (PD-1) 
      agents notably improved 2-year overall survival (OS) rates, compared to 
      docetaxel. NSCLC patients now receive nivolumab and irradiation, concurrently or 
      not. However, little is known about the safety of this combination, even though 
      the preclinical model suggested a possible synergic effect. We analyzed NSCLC 
      patients treated with radiotherapy and nivolumab according to former's timing. 
      METHODS: We retrospectively reviewed records of a large series of metastatic 
      NSCLC patients from three French centers, irradiated during the 6 months 
      preceding, concomitantly, or 3 months after nivolumab administration to assess 
      nivolumab tolerance and outcomes. RESULTS: Among 104 patients included (37 women; 
      67 men; median age 60.3 years; 67% with performance status <2; 93.2% were current 
      or past smokers) and their 144 intra- or extracranial irradiation courses, 
      any-grade adverse events (AEs) were observed in 62 (59.6%), with 10 (9.6%) 
      experiencing at least one grade 3/4 toxicity and 9 (8.7%) at least one grade 3/4 
      immune-related AE (IRAE). Respective 1- and 2-year OS rates were 48.8% and 29.1%, 
      while 1- and 2-year progression-free survival (PFS) rates were 20.9% and 10.1%. 
      PFS was significantly better for patients with IRAE(s) (P = 0.038) than those 
      without and a trend toward better OS (P = 0.06). Delivering radiation before or 
      during/after nivolumab administration was not associated with better OS or PFS. 
      CONCLUSION: Radiotherapy delivered during the 6 months before, during, or the 
      three months following nivolumab for NSCLCs was not associated with an increased 
      risk of severe or unexpected toxicities.
CI  - (c) 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Lesueur, Paul
AU  - Lesueur P
AUID- ORCID: 0000-0002-6200-845X
AD  - Radiation Oncology, Centre Francois Baclesse Centre de Lutte Contre le Cancer, 
      Caen, France.
FAU - Escande, Alexandre
AU  - Escande A
AD  - Radiation Oncology, Centre Oscar Lambret, Lille, France.
FAU - Thariat, Juliette
AU  - Thariat J
AD  - Radiation Oncology, Centre Francois Baclesse Centre de Lutte Contre le Cancer, 
      Caen, France.
FAU - Vauleon, Enora
AU  - Vauleon E
AD  - Medical Oncology, Centre Oscar Lambret, Lille, France.
FAU - Monnet, Isabelle
AU  - Monnet I
AD  - Onco-pneumology, Centre Hospitalier Intercommunal de Creteil, Ile-de-France, 
      France.
FAU - Cortot, Alexis
AU  - Cortot A
AD  - Pneumology, Centre Hospitalier Regional Universitaire de Lille, Lille, France.
FAU - Lerouge, Delphine
AU  - Lerouge D
AD  - Radiation Oncology, Centre Francois Baclesse Centre de Lutte Contre le Cancer, 
      Caen, France.
FAU - Danhier, Serge
AU  - Danhier S
AD  - Radiation Oncology, Centre Francois Baclesse Centre de Lutte Contre le Cancer, 
      Caen, France.
FAU - Do, Pascal
AU  - Do P
AD  - Onco-pneumology, Centre Francois Baclesse Centre de Lutte Contre le Cancer, Caen, 
      France.
FAU - Dubos-Arvis, Catherine
AU  - Dubos-Arvis C
AD  - Onco-pneumology, Centre Francois Baclesse Centre de Lutte Contre le Cancer, Caen, 
      France.
FAU - Chouaid, Christos
AU  - Chouaid C
AUID- ORCID: 0000-0002-4290-5524
AD  - Onco-pneumology, Centre Hospitalier Intercommunal de Creteil, Ile-de-France, 
      France.
FAU - Gervais, Radj
AU  - Gervais R
AD  - Onco-pneumology, Centre Francois Baclesse Centre de Lutte Contre le Cancer, Caen, 
      France.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20181011
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (PDCD1 protein, human)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
EIN - Cancer Med. 2019 Sep;8(12):5820. PMID: 31524336
MH  - Aged
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/*radiotherapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Nivolumab/*therapeutic use
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
MH  - Retrospective Studies
PMC - PMC6247050
OTO - NOTNLM
OT  - anti-PD-1
OT  - checkpoint inhibitor: radiotherapy
OT  - combination
OT  - nivolumab
OT  - safety
EDAT- 2018/10/13 06:00
MHDA- 2019/11/15 06:00
PMCR- 2018/10/11
CRDT- 2018/10/13 06:00
PHST- 2018/08/13 00:00 [received]
PHST- 2018/09/18 00:00 [revised]
PHST- 2018/09/19 00:00 [accepted]
PHST- 2018/10/13 06:00 [pubmed]
PHST- 2019/11/15 06:00 [medline]
PHST- 2018/10/13 06:00 [entrez]
PHST- 2018/10/11 00:00 [pmc-release]
AID - CAM41825 [pii]
AID - 10.1002/cam4.1825 [doi]
PST - ppublish
SO  - Cancer Med. 2018 Nov;7(11):5505-5513. doi: 10.1002/cam4.1825. Epub 2018 Oct 11.